Skip to main content
. 2020 Feb 6;11(2):96. doi: 10.1038/s41419-020-2296-4

Fig. 5. Effects of CRAMP on cardiomyocytes and MHECs.

Fig. 5

a NRCMs were treated with CRAMP (0.05, 0.15, or 0.5 mg/L) for 24 h. Fetal gene transcription (n = 6). b, c NRCMs were treated with CRAMP (0.5 mg/L) and Ang II (1 μM) for 24 h. b α-Actin staining (n = 6) and cell surface area (n > 50 cells per group). c ROS levels, SOD, Gpx, and NADPH oxidase activity in NRCMs (n = 6). d NOX2 and NOX4 level in NRCMs (n = 6). e–g MHECs were treated with CRAMP (0.05, 0.15, or 0.5 mg/L) and/or Ang II (1 μM) for 24 h. e Cell viability (n = 6). f TNFα, IL-1, IL-6 levels in MHECs (n = 6). g ROS levels, SOD, Gpx, and NADPH oxidase activity in MHECs (n = 6). *P < 0.05 vs. CON; #P < 0.05 vs. Ang II.